Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Completed · Not applicable · Has a placebo group
Conditions studied: Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
In brief
Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).
Key facts
- Study ID
- NCT05447650
- Run by
- i-Lumen Scientific, Inc.
- People needed
- 95
- Starts
- 2022-04-12
- Expected to finish
- 2025-06-15
- Last updated by the study team
- 2025-06-24
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Associated Retina Consultants — Phoenix, Arizona, United States
- Bay Area Retina Associates — Walnut Creek, California, United States
- University Retina and Macula Associates, PC — Lemont, Illinois, United States
- Cumberland Valley Retina Consultants — Chambersburg, Pennsylvania, United States
- Erie Retina Research, LLC — Erie, Pennsylvania, United States
- Charles Retina Institute — Germantown, Tennessee, United States
- Austin Research Center for Retina — Austin, Texas, United States
- Retina Consultants of Texas — Bellaire, Texas, United States
- Star Retina — Burleson, Texas, United States
- Texas Retina Associates — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.